% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
\PassOptionsToPackage{dvipsnames,svgnames,x11names}{xcolor}
%
\documentclass[
  letterpaper,
  DIV=11,
  numbers=noendperiod]{scrartcl}

\usepackage{amsmath,amssymb}
\usepackage{iftex}
\ifPDFTeX
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
\usepackage{lmodern}
\ifPDFTeX\else  
    % xetex/luatex font selection
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\setlength{\emergencystretch}{3em} % prevent overfull lines
\setcounter{secnumdepth}{5}
% Make \paragraph and \subparagraph free-standing
\ifx\paragraph\undefined\else
  \let\oldparagraph\paragraph
  \renewcommand{\paragraph}[1]{\oldparagraph{#1}\mbox{}}
\fi
\ifx\subparagraph\undefined\else
  \let\oldsubparagraph\subparagraph
  \renewcommand{\subparagraph}[1]{\oldsubparagraph{#1}\mbox{}}
\fi


\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}\usepackage{longtable,booktabs,array}
\usepackage{calc} % for calculating minipage widths
% Correct order of tables after \paragraph or \subparagraph
\usepackage{etoolbox}
\makeatletter
\patchcmd\longtable{\par}{\if@noskipsec\mbox{}\fi\par}{}{}
\makeatother
% Allow footnotes in longtable head/foot
\IfFileExists{footnotehyper.sty}{\usepackage{footnotehyper}}{\usepackage{footnote}}
\makesavenoteenv{longtable}
\usepackage{graphicx}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
% definitions for citeproc citations
\NewDocumentCommand\citeproctext{}{}
\NewDocumentCommand\citeproc{mm}{%
  \begingroup\def\citeproctext{#2}\cite{#1}\endgroup}
\makeatletter
 % allow citations to break across lines
 \let\@cite@ofmt\@firstofone
 % avoid brackets around text for \cite:
 \def\@biblabel#1{}
 \def\@cite#1#2{{#1\if@tempswa , #2\fi}}
\makeatother
\newlength{\cslhangindent}
\setlength{\cslhangindent}{1.5em}
\newlength{\csllabelwidth}
\setlength{\csllabelwidth}{3em}
\newenvironment{CSLReferences}[2] % #1 hanging-indent, #2 entry-spacing
 {\begin{list}{}{%
  \setlength{\itemindent}{0pt}
  \setlength{\leftmargin}{0pt}
  \setlength{\parsep}{0pt}
  % turn on hanging indent if param 1 is 1
  \ifodd #1
   \setlength{\leftmargin}{\cslhangindent}
   \setlength{\itemindent}{-1\cslhangindent}
  \fi
  % set entry spacing
  \setlength{\itemsep}{#2\baselineskip}}}
 {\end{list}}
\usepackage{calc}
\newcommand{\CSLBlock}[1]{\hfill\break\parbox[t]{\linewidth}{\strut\ignorespaces#1\strut}}
\newcommand{\CSLLeftMargin}[1]{\parbox[t]{\csllabelwidth}{\strut#1\strut}}
\newcommand{\CSLRightInline}[1]{\parbox[t]{\linewidth - \csllabelwidth}{\strut#1\strut}}
\newcommand{\CSLIndent}[1]{\hspace{\cslhangindent}#1}

\KOMAoption{captions}{tableheading}
\makeatletter
\@ifpackageloaded{tcolorbox}{}{\usepackage[skins,breakable]{tcolorbox}}
\@ifpackageloaded{fontawesome5}{}{\usepackage{fontawesome5}}
\definecolor{quarto-callout-color}{HTML}{909090}
\definecolor{quarto-callout-note-color}{HTML}{0758E5}
\definecolor{quarto-callout-important-color}{HTML}{CC1914}
\definecolor{quarto-callout-warning-color}{HTML}{EB9113}
\definecolor{quarto-callout-tip-color}{HTML}{00A047}
\definecolor{quarto-callout-caution-color}{HTML}{FC5300}
\definecolor{quarto-callout-color-frame}{HTML}{acacac}
\definecolor{quarto-callout-note-color-frame}{HTML}{4582ec}
\definecolor{quarto-callout-important-color-frame}{HTML}{d9534f}
\definecolor{quarto-callout-warning-color-frame}{HTML}{f0ad4e}
\definecolor{quarto-callout-tip-color-frame}{HTML}{02b875}
\definecolor{quarto-callout-caution-color-frame}{HTML}{fd7e14}
\makeatother
\makeatletter
\@ifpackageloaded{caption}{}{\usepackage{caption}}
\AtBeginDocument{%
\ifdefined\contentsname
  \renewcommand*\contentsname{Table of contents}
\else
  \newcommand\contentsname{Table of contents}
\fi
\ifdefined\listfigurename
  \renewcommand*\listfigurename{List of Figures}
\else
  \newcommand\listfigurename{List of Figures}
\fi
\ifdefined\listtablename
  \renewcommand*\listtablename{List of Tables}
\else
  \newcommand\listtablename{List of Tables}
\fi
\ifdefined\figurename
  \renewcommand*\figurename{Figure}
\else
  \newcommand\figurename{Figure}
\fi
\ifdefined\tablename
  \renewcommand*\tablename{Table}
\else
  \newcommand\tablename{Table}
\fi
}
\@ifpackageloaded{float}{}{\usepackage{float}}
\floatstyle{ruled}
\@ifundefined{c@chapter}{\newfloat{codelisting}{h}{lop}}{\newfloat{codelisting}{h}{lop}[chapter]}
\floatname{codelisting}{Listing}
\newcommand*\listoflistings{\listof{codelisting}{List of Listings}}
\makeatother
\makeatletter
\makeatother
\makeatletter
\@ifpackageloaded{caption}{}{\usepackage{caption}}
\@ifpackageloaded{subcaption}{}{\usepackage{subcaption}}
\makeatother
\ifLuaTeX
  \usepackage{selnolig}  % disable illegal ligatures
\fi
\usepackage{bookmark}

\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\urlstyle{same} % disable monospaced font for URLs
\hypersetup{
  pdftitle={Development and Validation of a Risk Prediction Model of linezolid-induced thrombocytopenia in Vietnamese patients},
  colorlinks=true,
  linkcolor={blue},
  filecolor={Maroon},
  citecolor={Blue},
  urlcolor={Blue},
  pdfcreator={LaTeX via pandoc}}

\title{Development and Validation of a Risk Prediction Model of
linezolid-induced thrombocytopenia in Vietnamese patients}
\author{Nhi Nguyen Ha \and An Tang Quoc}
\date{Friday, March 22, 2024}

\begin{document}
\maketitle
\begin{abstract}
Write abstract here, note the indentation
\end{abstract}

\section{Checklist}\label{checklist}

\begin{longtable}[]{@{}
  >{\raggedright\arraybackslash}p{(\columnwidth - 6\tabcolsep) * \real{0.2466}}
  >{\centering\arraybackslash}p{(\columnwidth - 6\tabcolsep) * \real{0.2466}}
  >{\raggedright\arraybackslash}p{(\columnwidth - 6\tabcolsep) * \real{0.2603}}
  >{\centering\arraybackslash}p{(\columnwidth - 6\tabcolsep) * \real{0.2466}}@{}}
\caption{TRIPOD-Cluster checklist of items to include when reporting a
study developing or validating a multivariable prediction model using
clustered data}\tabularnewline
\toprule\noalign{}
\begin{minipage}[b]{\linewidth}\raggedright
\textbf{Section/topic}
\end{minipage} & \begin{minipage}[b]{\linewidth}\centering
\textbf{Item No}
\end{minipage} & \begin{minipage}[b]{\linewidth}\raggedright
\textbf{Description}
\end{minipage} & \begin{minipage}[b]{\linewidth}\centering
\textbf{Draft date}
\end{minipage} \\
\midrule\noalign{}
\endfirsthead
\toprule\noalign{}
\begin{minipage}[b]{\linewidth}\raggedright
\textbf{Section/topic}
\end{minipage} & \begin{minipage}[b]{\linewidth}\centering
\textbf{Item No}
\end{minipage} & \begin{minipage}[b]{\linewidth}\raggedright
\textbf{Description}
\end{minipage} & \begin{minipage}[b]{\linewidth}\centering
\textbf{Draft date}
\end{minipage} \\
\midrule\noalign{}
\endhead
\bottomrule\noalign{}
\endlastfoot
\textbf{Title and abstract} & & & \\
Title & 1 & Identify the study as developing and/or validating a
multivariable prediction model, the target population, and the outcome
to be predicted & \\
Abstract & 2 & Provide a summary of research objectives, setting,
participants, data source, sample size, predictors, outcome, statistical
analysis, results, and conclusions* & \\
\textbf{Introduction} & & & \\
Background and objectives & 3a & Explain the medical context (including
whether diagnostic or prognostic) and rationale for developing or
validating the prediction model, including references to existing
models, and the advantages of the study design* & \\
& 3b & Specify the objectives, including whether the study describes the
development or validation of the model* & \\
\textbf{Methods} & & & \\
Participants and data & 4a & Describe eligibility criteria for
participants and datasets* & \\
& 4b & Describe the origin of the data, and how the data were
identified, requested, and collected & \\
Sample size & 5 & Explain how the sample size was arrived at* & Mar
21 \\
Outcomes and predictors & 6a & Define the outcome that is predicted by
the model, including how and when assessed* & Mar 21 \\
& 6b & Define all predictors used in developing or validating the model,
including how and when measured* & \\
Data preparation & 7a & Describe how the data were prepared for
analysis, including any cleaning, harmonisation, linkage, and quality
checks & \\
& 7b & Describe the method for assessing risk of bias and applicability
in the individual clusters (eg, using PROBAST) & \\
& 7c & For validation, identify any differences in definition and
measurement from the development data (eg, setting, eligibility
criteria, outcome, predictors)* & \\
& 7d & Describe how missing data were handled* & \\
Data analysis & 8a & Describe how predictors were handled in the
analyses & \\
& 8b & Specify the type of model, all model building procedures (eg, any
predictor selection and penalisation), and method for validation* & \\
& 8c & Describe how any heterogeneity across clusters (eg, studies or
settings) in model parameter values was handled & \\
& 8d & For validation, describe how the predictions were calculated & \\
& 8e & Specify all measures used to assess model performance (eg,
calibration, discrimination, and decision curve analysis) and, if
relevant, to compare multiple models & \\
& 8f & Describe how any heterogeneity across clusters (eg, studies or
settings) in model performance was handled and quantified & \\
& 8g & Describe any model updating (eg, recalibration) arising from the
validation, either overall or for particular populations or settings*
& \\
Sensitivity analysis & 9 & Describe any planned subgroup or sensitivity
analysis---eg, assessing performance according to sources of bias,
participant characteristics, setting & \\
\textbf{Results} & & & \\
Participants and datasets & 10a & Describe the number of clusters and
participants from data identified through to data analysed; a flowchart
might be helpful* & \\
& 10b & Report the characteristics overall and where applicable for each
data source or setting, including the key dates, predictors, treatments
received, sample size, number of outcome events, follow-up time, and
amount of missing data* & \\
& 10c & For validation, show a comparison with the development data of
the distribution of important variables (demographics, predictors, and
outcome) & \\
Risk of bias & 11 & Report the results of the risk-of-bias assessment in
the individual clusters & \\
Model development and specification & 12a & Report the results of any
assessments of heterogeneity across clusters that led to subsequent
actions during the model's development (eg, inclusion or exclusion of
particular predictors or clusters) & \\
& 12b & Present the final prediction model (ie, all regression
coefficients, and model intercept or baseline estimate of the outcome at
a given time point) and explain how to use it for predictions in new
individuals* & \\
Model performance & 13a & Report performance measures (with uncertainty
intervals) for the prediction model, overall and for each cluster & \\
& 13b & Report results of any heterogeneity across clusters in model
performance & \\
Model updating & 14 & Report the results from any model updating
(including the updated model equation and subsequent performance),
overall and for each cluster* & \\
Sensitivity analysis & 15 & Report results from any subgroup or
sensitivity analysis & \\
\textbf{Discussion} & & & \\
Interpretation & 16a & Give an overall interpretation of the main
results, including heterogeneity across clusters in model performance,
in the context of the objectives and previous studies* & \\
& 16b & For validation, discuss the results with reference to the model
performance in the development data, and in any previous validations
& \\
& 16c & Discuss the strengths of the study and any limitations (eg,
missing or incomplete data, non-representativeness, data harmonisation
problems) & \\
Implications & 17 & Discuss the potential use of the model and
implications for future research, with specific view to generalisability
and applicability of the model across different settings or
(sub)populations & \\
\textbf{Other information} & & & \\
Supplementary information & 18 & Provide information about the
availability of supplementary resources (eg, study protocol, analysis
code, datasets)* & \\
Funding & 19 & Give the source of funding and the role of the funders
for the present study & \\
\end{longtable}

\section{Introduction}\label{introduction}

\subsection{Background and objectives}\label{background-and-objectives}

Linezolid is an oxazolidinones antibiotics {[}1{]}.

\section{Methods}\label{methods}

\subsection{Participants and data}\label{participants-and-data}

\subsection{Sample size}\label{sample-size}

Previous studies developing logistic regression models for LI-TP risk
predictions have included 4-6 predictors in their final models {[}2{]};
{[}3{]}; {[}4{]}; {[}5{]}. We expect to include about as many candidate
predictors, based on results from the expert opinion survey and the
Bayesian Model Selection algorithm
see~\ref{sec-outcomes-and-predictors}. Some of the candidate predictors
might be continuous, which may potentially require non-linear modelling
and therefore slightly increase the number of variables.

A general rule of thumb is for at least 10 events be available for each
candidate predictor considered in a prediction model {[}6{]}. We have a
total of 816 eligible patients and 264 of those have experienced the
outcome. If the number of candidate predictors is 7, we would have 37
events per candidate predictor, which is considerably greater than the
minimum number required. Even if the number of parameters screened is
20, we would still have 13 events per candidate predictor.

However, the aforementioned rule of thumb have generated some debate in
the literature, with recent results suggesting that event per variable
criterion is too simplistic and has no strong relation to the predictive
performance of a model. Riley et al {[}7{]} proposed a different set of
criteria to estimate minimum sample size for models developed using
logistic regression, which are the following:

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\tightlist
\item
  Small optimism in predictor effect estimates, defined as a global
  shrinkage factor of \textgreater= 0.9.
\item
  Small absolute difference of \textless= 0.05 in the model's apparent
  and adjusted Nagelkerke's R-squared.
\item
  Precise estimation of the overall risk in the population.
\end{enumerate}

Criteria 1 and 2 aims to reduce the potential of overfitting. Criteria 3
aims to ensure the overall risk is estimated precisely.

\subsubsection{Step 1: Choose the number of candidate predictors of
interest for inclusion in the model, and calculate the corresponding
number of predictor parameters
(p)}\label{step-1-choose-the-number-of-candidate-predictors-of-interest-for-inclusion-in-the-model-and-calculate-the-corresponding-number-of-predictor-parameters-p}

Note that one predictor may require two or more parameters. For example,
a k-category predictor requires k-1 parameters and a continuous
predictor model with a non-linear trend requires more than one parameter
to be estimated. Also include any potential interaction terms towards
the total p.

When using a predictor selection method, p should be defined as the
total number of parameters screened, and not just the subset that are
included in the final model.

Assuming maximum total p to be 20.

\begin{tcolorbox}[enhanced jigsaw, colback=white, title=\textcolor{quarto-callout-note-color}{\faInfo}\hspace{0.5em}{Note}, opacityback=0, opacitybacktitle=0.6, bottomtitle=1mm, leftrule=.75mm, toprule=.15mm, bottomrule=.15mm, breakable, toptitle=1mm, titlerule=0mm, arc=.35mm, rightrule=.15mm, colframe=quarto-callout-note-color-frame, coltitle=black, left=2mm, colbacktitle=quarto-callout-note-color!10!white]

The value of p is assumed to be no larger than 20 because univariate
regression shows there are 20 variables that are significantly
correlated with the outcome.

\end{tcolorbox}

\textsubscript{Source:
\href{https://AnTangQuoc.github.io/LZD-TP-pred-model/index.qmd.html}{Article
Notebook}}

\subsubsection{\texorpdfstring{Step 2: Choose sensible values for
R\textsuperscript{2}\textsubscript{CS\_adj} and
max(R\textsuperscript{2}\textsubscript{CS\_app}) based on previous
studies where R\textsuperscript{2}\textsubscript{CS} is the Cox-Snell
R\textsuperscript{2}
statistic.}{Step 2: Choose sensible values for R2CS\_adj and max(R2CS\_app) based on previous studies where R2CS is the Cox-Snell R2 statistic.}}\label{step-2-choose-sensible-values-for-r2cs_adj-and-maxr2cs_app-based-on-previous-studies-where-r2cs-is-the-cox-snell-r2-statistic.}

The value of max(R\textsuperscript{2}\textsubscript{CS\_app}) is based
on the overall prevalence or overall rate of the outcome in the
population of interest. The incidence of LI-TP in patients treated with
linezolid was estimated to be 37\% in a meta-analysis by Zhao et al
{[}8{]}.

The value of R\textsuperscript{2}\textsubscript{CS\_adj} could be based
on that for a previously published model in the same setting and
population (with similar outcome definition). However, as previous
studies does not provide any information to identify a sensible value of
the minimum expected Cox-Snell R\textsuperscript{2}, the value
R\textsuperscript{2}\textsubscript{CS\_adj} will be assumed to
correspond to a R\textsuperscript{2}\textsubscript{Nagelkerke} of 0.15.

\begin{verbatim}
[1] 0.2048324
\end{verbatim}

\textsubscript{Source:
\href{https://AnTangQuoc.github.io/LZD-TP-pred-model/index.qmd.html}{Article
Notebook}}

\subsubsection{Step 3: Criterion 1}\label{step-3-criterion-1}

Calculate the sample size required to ensure Van Houwelingen's global
shrinkage factor (S\textsubscript{VH}) is close to 1. A value of
S\textsubscript{VH} \textgreater= 0.90 is generally recommended, which
reflects a small amount of overfitting during model development.

\begin{verbatim}
[1] 775
\end{verbatim}

\textsubscript{Source:
\href{https://AnTangQuoc.github.io/LZD-TP-pred-model/index.qmd.html}{Article
Notebook}}

We see that 775 participants are required to meet criterion 1.

\subsubsection{Step 4: Criterion 2}\label{step-4-criterion-2}

Calculate the shrinkage factor (S\textsubscript{VH}) required to ensure
a small absolute difference of \textless= 0.05 in the developed model's
apparent and adjusted Nagelkerke's R\textsuperscript{2}. Then derive the
required sample size conditional on this value of S\textsubscript{VH}.

\begin{verbatim}
[1] 478
\end{verbatim}

\textsubscript{Source:
\href{https://AnTangQuoc.github.io/LZD-TP-pred-model/index.qmd.html}{Article
Notebook}}

We see that 478 participants are required to meet criterion 2.

\subsubsection{Step 5: Criterion 3}\label{step-5-criterion-3}

Calculate the sample size required to ensure a precise estimate of the
overall risk in the population. The suggested absolute margin of error
is \textless= 0.05.

\begin{verbatim}
[1] 359
\end{verbatim}

\textsubscript{Source:
\href{https://AnTangQuoc.github.io/LZD-TP-pred-model/index.qmd.html}{Article
Notebook}}

We see that 359 participants are required to meet criterion 3.

\subsubsection{Step 6: Final sample
size}\label{step-6-final-sample-size}

The required minimum sample size is the maximum value from steps 3 to 5,
to ensure that each of criteria 1 to 3 are met.

\begin{verbatim}
[1] 775
\end{verbatim}

\textsubscript{Source:
\href{https://AnTangQuoc.github.io/LZD-TP-pred-model/index.qmd.html}{Article
Notebook}}

The final estimate of minimum sample size is 775, therefore our data is
sufficient for model development with at most 20 parameters.

\subsection{Outcomes and predictors}\label{sec-outcomes-and-predictors}

\subsubsection{6a. Define the outcome that is predicted by the model,
including how and when
assessed}\label{a.-define-the-outcome-that-is-predicted-by-the-model-including-how-and-when-assessed}

The outcome of interest is linezolid-induced thrombocytopenia, defined
as (i) a platelet count of \textless{} 112.5 x 10\textsuperscript{9}
cells/L (75\% of the lower limit of normal) for patients with a baseline
platelet count in the normal range; (ii) A reduction in platelet count
of ≥ 25\% from the baseline value for patients with a baseline platelet
count of \textless{} 150 x 10\textsuperscript{9} cells/L {[}9{]};
{[}5{]}; {[}10{]}.

Normal platelet count is defined as 150-450 x 10\textsuperscript{9}
cells/L. Baseline platelet count is defined as the last recorded PLT
value before the start of linezolid therapy. Participants are considered
to have met the outcome if they have a platelet count that meets the
above criteria at any time during linezolid therapy or within 5 days
after the end of therapy.

\begin{tcolorbox}[enhanced jigsaw, colback=white, title=\textcolor{quarto-callout-warning-color}{\faExclamationTriangle}\hspace{0.5em}{Warning}, opacityback=0, opacitybacktitle=0.6, bottomtitle=1mm, leftrule=.75mm, toprule=.15mm, bottomrule=.15mm, breakable, toptitle=1mm, titlerule=0mm, arc=.35mm, rightrule=.15mm, colframe=quarto-callout-warning-color-frame, coltitle=black, left=2mm, colbacktitle=quarto-callout-warning-color!10!white]

Thrombocytopenia may occur within a few days after stopping LZD, when
the drug hasn't been completely eliminated. However, it is unknown
exactly how long after stopping LZD can a TP event still be attributed
to LZD use. The value of 5 days has been chosen \emph{almost}
arbitrarily.

Our rationale is that after 5 days (120 hrs), LZD is guaranteed to be
completely eliminated in all patients, as the longest
t\textsubscript{1/2} is 8.3 ± 2.4 hrs in end-stage renal disease
patients, +3 SD would be \textasciitilde16 hrs, so 120 hrs is
\textgreater7 half-lives, therefore in patients with the worst
clearance, 99\% of them would have 99\% of the drug eliminated from
their systems. Furthermore, trough LZD concentration
(C\textsubscript{min}) has previously been identified as a predictor of
LI-TP development, and LI-TP itself is mostly reversible after
discontinuation, so we would argue that any TP events that occur after
LZD has been eliminated from the system would not be related to LZD use.

\end{tcolorbox}

\subsubsection{6b. Define all predictors used in developing or
validating the model, including how and when
measured}\label{b.-define-all-predictors-used-in-developing-or-validating-the-model-including-how-and-when-measured}

\subsection{Data preparation}\label{data-preparation}

\subsubsection{7a. Describe how the data were prepared for analysis,
including any cleaning, harmonisation, linkage, and quality
checks}\label{a.-describe-how-the-data-were-prepared-for-analysis-including-any-cleaning-harmonisation-linkage-and-quality-checks}

\subsection{Data analysis}\label{data-analysis}

\subsection{Sensitivity analysis}\label{sensitivity-analysis}

\section{Results}\label{results}

\subsection{Participants and datasets}\label{participants-and-datasets}

\subsection{Risk of bias}\label{risk-of-bias}

\subsection{Model development and
specification}\label{model-development-and-specification}

\subsection{Model performance}\label{model-performance}

\subsection{Model updating}\label{model-updating}

\subsection{Sensitivity analysis}\label{sensitivity-analysis-1}

\section{Discussion}\label{discussion}

\subsection{Interpretation}\label{interpretation}

\subsection{Implications}\label{implications}

\section{Other information}\label{other-information}

\subsection{Supplementary information}\label{supplementary-information}

\subsection{Funding}\label{funding}

\subsection{References}\label{references}

\phantomsection\label{refs}
\begin{CSLReferences}{0}{1}
\bibitem[\citeproctext]{ref-cazavet_risk_2020}
1. Cazavet J, Bounes FV, Ruiz S, Seguin T, Crognier L, Rouget A, et al.
Risk factor analysis for linezolid-associated thrombocytopenia in
critically ill patients. Eur J Clin Microbiol Infect Dis {[}Internet{]}.
2020;39:527--38. Available from:
\url{https://www.ncbi.nlm.nih.gov/pubmed/31853741}

\bibitem[\citeproctext]{ref-liu_analysis_2021}
2. Liu Y, Liu T, Wei G, Yan P, Fang X, Xie L. Analysis of risk factors
and establishment of risk prediction model for linezolid-associated
thrombocytopenia. Medical Journal of Chinese People's Liberation Army
{[}Internet{]}. 2021;46. Available from:
\url{https://d.wanfangdata.com.cn/periodical/jfjyxzz202108006}

\bibitem[\citeproctext]{ref-duan_regression_2022}
3. Duan L, Zhou Q, Feng Z, Zhu C, Cai Y, Wang S, et al. A {Regression}
{Model} to {Predict} {Linezolid} {Induced} {Thrombocytopenia} in
{Neonatal} {Sepsis} {Patients}: {A} {Ten}-{Year} {Retrospective}
{Cohort} {Study}. Front Pharmacol {[}Internet{]}. 2022;13:710099.
Available from: \url{https://www.ncbi.nlm.nih.gov/pubmed/35185555}

\bibitem[\citeproctext]{ref-qin_development_2021}
4. Qin Y, Chen Z, Gao S, Pan MK, Li YX, Lv ZQ, et al. Development and
{Validation} of a {Risk} {Prediction} {Model} of {Linezolid}-induced
{Thrombocytopenia} in {Elderly} {Patients} {[}Internet{]}. In Review;
2021 Jun. Available from:
\url{https://www.researchsquare.com/article/rs-582799/v1}

\bibitem[\citeproctext]{ref-xu_establishment_2023}
5. Xu J, Lu J, Yuan Y, Duan L, Shi L, Chen F, et al.
\href{https://doi.org/10.1093/jac/dkad191}{Establishment and validation
of a risk prediction model incorporating concentrations of linezolid and
its metabolite {PNU142300} for linezolid-induced thrombocytopenia}. The
Journal of Antimicrobial Chemotherapy. 2023;78:1974--81.

\bibitem[\citeproctext]{ref-peduzzi1995}
6. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events
per independent variable in proportional hazards regression analysis II.
Accuracy and precision of regression estimates. Journal of Clinical
Epidemiology {[}Internet{]}. 1995;48:1503--10. Available from:
\url{https://www.jclinepi.com/article/0895-4356(95)00048-8/abstract}

\bibitem[\citeproctext]{ref-riley2019}
7. Riley RD, Snell KI, Ensor J, Burke DL, Harrell Jr FE, Moons KG, et
al. Minimum sample size for developing a multivariable prediction model:
PART II - binary and time-to-event outcomes. Statistics in Medicine
{[}Internet{]}. 2019;38:1276--96. Available from:
\url{https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.7992}

\bibitem[\citeproctext]{ref-zhao_prediction_2024}
8. Zhao X, Peng Q, Hu D, Li W, Ji Q, Dong Q, et al. Prediction of risk
factors for linezolid-induced thrombocytopenia based on neural network
model. Frontiers in Pharmacology {[}Internet{]}. 2024 {[}cited 2024 Feb
27{]};15. Available from:
\url{https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1292828}

\bibitem[\citeproctext]{ref-zyvoxpr}
9. Zyvox prescribing information {[}Internet{]}. Available from:
\url{https://labeling.pfizer.com/showlabeling.aspx?id=649}

\bibitem[\citeproctext]{ref-kawasuji_proposal_2021}
10. Kawasuji H, Tsuji Y, Ogami C, Kimoto K, Ueno A, Miyajima Y, et al.
Proposal of initial and maintenance dosing regimens with linezolid for
renal impairment patients. BMC Pharmacology and Toxicology
{[}Internet{]}. 2021 {[}cited 2024 Feb 26{]};22:13. Available from:
\url{https://doi.org/10.1186/s40360-021-00479-w}

\end{CSLReferences}



\end{document}
